IFNλ stimulates MxA production in human dermal fibroblasts via a MAPK-dependent STAT1-independent mechanism

Journal of Investigative Dermatology

Volumn 135, Issue 12, 2015, Pages 2935-2943

  Alase, Adewonuola A ^a   El Sherbiny, Yasser M ^b,c   Vital, Edward M ^b   Tobin, Desmond J ^a   Turner, Neil A ^d   Wittmann, Miriam ^a,b,e,f  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c MANSOURA UNIVERSITY   (Egypt)

^d UNIVERSITY OF LEEDS   (United Kingdom)

^e ST LUKE S HOSPITAL   (United Kingdom)

^f CHAPEL ALLERTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ALPHA INTERFERON; COLLAGEN; INTERFERON; INTERFERON LAMBDA; INTERFERON LAMBDA RECEPTOR 1; INTERFERON RECEPTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; MYXOVIRUS RESISTANCE PROTEIN A; STAT1 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MX1 PROTEIN, HUMAN; MYXOVIRUS RESISTANCE PROTEIN; STAT1 PROTEIN, HUMAN;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; HUMAN CELL; KERATINOCYTE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; SKIN FIBROBLAST; WESTERN BLOTTING; BIOSYNTHESIS; CELL CULTURE; CYTOLOGY; FIBROBLAST; METABOLISM; PHYSIOLOGY; SKIN;

CELLS, CULTURED; FIBROBLASTS; HUMANS; INTERFERON-ALPHA; INTERFERON-GAMMA; MITOGEN-ACTIVATED PROTEIN KINASES; MYXOVIRUS RESISTANCE PROTEINS; RECEPTORS, INTERFERON; SKIN; STAT1 TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84948713905     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2015.317     Document Type: Article

References (51)

1. Abushahba W, Balan M, Castaneda I, et al. (2010). Antitumor activity of type I and type III interferons in BNL hepatoma model. Cancer Immunol Immunother 59: 1059-71
2. Ank N, Iversen MB, Bartholdy C, et al. (2008). An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity. J Immunol 180: 2474-85
3. Bachmann M, Ulziibat S, Hardle L, et al. (2013). IFNalpha converts IL-22 into a cytokine efficiently activating STAT1 and its downstream targets. Biochem Pharmacol 85: 396-403
4. Bolen CR, Ding S, Robek MD, et al. (2014). Dynamic expression profiling of type I and type III interferon-stimulated hepatocytes reveals a stable hierarchy of gene expression. Hepatology 59: 1262-72
5. Capaldo CT, Beeman N, Hilgarth RS, et al. (2012). IFN-gamma and TNF-Alphainduced GBP-1 inhibits epithelial cell proliferation through suppression of beta-catenin/TCF signaling. Mucosal Immunol 5: 681-90
6. Chai Y, Huang HL, Hu DJ, et al. (2011). IL-29 and IFN-Alpha regulate the expression of MxA, 2', 5'-OAS and PKR genes in association with the activation of Raf-MEK-ERK and PI3K-AKT signal pathways in HepG2.2.15 cells. Mol Biol Rep 38: 139-43
7. Clark AR, Dean JL, Saklatvala J. (2003). Post-Transcriptional regulation of gene expression by mitogen-Activated protein kinase p38. FEBS Lett 546: 37-44
8. Dai J, Megjugorac NJ, Gallagher GE, et al. (2009). IFN-lambda1 (IL-29) inhibits GATA3 expression and suppresses Th2 responses in human naive and memory T cells. Blood 113: 5829-38
9. Dickensheets H, Sheikh F, Park O, et al. (2013). Interferon-lambda (IFN-lambda) induces signal transduction and gene expression in human hepatocytes, but not in lymphocytes or monocytes. J Leukoc Biol 93: 377-85
10. Duong FH, Trincucci G, Boldanova T, et al. (2014). IFN-lambda receptor 1 expression is induced in chronic hepatitis C and correlates with the IFN-lambda3 genotype and with nonresponsiveness to IFN-Alpha therapies. J Exp Med 211: 857-68
11. Egli A, Levin A, Santer DM, et al. (2014). Immunomodulatory Function of Interleukin 28B during primary infection with cytomegalovirus. J InfectDis 210: 717-27
12. Eickelberg O, Pansky A, Koehler E, et al. (2001). Molecular mechanisms of TGF-(beta) antagonism by interferon (gamma) and cyclosporine A in lung fibroblasts. FASEB J 15: 797-806
13. Ghosh AK, Yuan W, Mori Y, et al. (2001). Antagonistic regulation of type I collagen gene expression by interferon-gamma and transforming growth factor-beta. Integration at the level of p300/CBP transcriptional coactivators. J Biol Chem 276: 11041-8
14. Goh KC, Haque SJ, Williams BR. (1999). p38 MAP kinase is required for STAT1 serine phosphorylation and transcriptional activation induced by interferons. EMBO J 18: 5601-8
15. Gough DJ, Levy DE, Johnstone RW, et al. (2008). IFNgamma signaling-does it mean JAK-STAT?. Cytokine Growth Factor Rev 19: 383-94
16. Hasegawa T, Nakao A, Sumiyoshi K, et al. (2003). IFN-gamma fails to antagonize fibrotic effect of TGF-beta on keloid-derived dermal fibroblasts. J Dermatol Sci 32: 19-24
17. Heino J. (2007). The collagen family members as cell adhesion proteins. BioEssays 29: 1001-10
18. Joshi S, Kaur S, Kroczynska B, et al. (2010). Mechanisms of mRNA translation of interferon stimulated genes. Cytokine 52: 123-7
19. Kotenko SV, Gallagher G, Baurin VV, et al. (2003). IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 4: 69-77
20. Lasfar A, Abushahba W, Balan M, et al. (2011). Interferon lambda: a new sword in cancer immunotherapy. Clin Dev Immunol 2011: 349575
21. Li Y, Sassano A, Majchrzak B, et al. (2004). Role of p38alpha Map kinase in Type I interferon signaling. J Biol Chem 279: 970-9
22. Liu BS, Janssen HL, Boonstra A. (2011). IL-29 and IFNalpha differ in their ability to modulate IL-12 production by TLR-Activated human macrophages and exhibit differential regulation of the IFNgamma receptor expression. Blood 117: 2385-95
23. Lutfalla G, Holland SJ, Cinato E, et al. (1995). Mutant U5A cells are complemented by an interferon-Alpha beta receptor subunit generated by alternative processing of a new member of a cytokine receptor gene cluster. EMBO J 14: 5100-8
24. MacMicking JD. (2012). Interferon-inducible effector mechanisms in cellautonomous immunity. Nat Rev Immunol 12: 367-82
25. Maher SG, Sheikh F, Scarzello AJ, et al. (2008). IFNalpha and IFNlambda differ in their antiproliferative effects and duration of JAK/STAT signaling activity. Cancer Biol Ther 7: 1109-15
26. Mennechet FJ, Uze G. (2006). Interferon-lambda-Treated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cells. Blood 107: 4417-23
27. Meyer O. (2009). Interferons and autoimmune disorders. Joint Bone Spine 76: 464-73
28. Miknis ZJ, Magracheva E, Li W, et al. (2010). Crystal structure of human interferon-lambda1 in complex with its high-Affinity receptor interferonlambdaR1. J Mol Biol 404: 650-64
29. Naschberger E, Wenzel J, Kretz CC, et al. (2010). Increased expression of guanylate binding protein-1 in lesional skin of patients with cutaneous lupus erythematosus. Exp Dermatol 20: 102-6
30. Nguyen VA, Chen J, Hong F, et al. (2000). Interferons activate the p42/44 mitogen-Activated protein kinase and JAK-STAT (Janus kinase-signal transducer and activator transcription factor) signalling pathways in hepatocytes: differential regulation by acute ethanol via a protein kinase C-dependent mechanism. Biochem J 349: 427-34
31. Nyberg F, Fransson J, Stephansson E. (2000). Proliferation and effects of UVA irradiation in cultured fibroblasts from lesions in cutaneous lupus erythematosus. Exp Dermatol 9: 53-7
32. Nystrom A, Velati D, Mittapalli VR, et al. (2013). Collagen VII plays a dual role in wound healing. J Clin Invest 123: 3498-509
33. Oliveira GV, Hawkins HK, Chinkes D, et al. (2009). Hypertrophic versus non hypertrophic scars compared by immunohistochemistry and laser confocal microscopy: type I and III collagens. Int Wound J 6: 445-52
34. Platanias LC. (2003). The p38 mitogen-Activated protein kinase pathway and its role in interferon signaling. Pharmacol Ther 98: 129-42
35. Prokunina-Olsson L, Muchmore B, Tang W, et al. (2013). A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 45: 164-71
36. Ronnblom L, Eloranta ML. (2013). The interferon signature in autoimmune diseases. Curr Opin Rheumatol 25: 248-53
37. Sadler AJ, Williams BR. (2008). Interferon-inducible antiviral effectors. Nat Rev Immunol 8: 559-68
38. Sheppard P, Kindsvogel W, Xu W, et al. (2003). IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 4: 63-8
39. Sommereyns C, Paul S, Staeheli P, et al. (2008). IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog 4: e1000017
40. Steen HC, Gamero AM. (2010). Interferon-lambda as a potential therapeutic agent in cancer treatment. J Interferon Cytokine Res 30: 597-602
41. Uddin S, Lekmine F, Sharma N, et al. (2000). The Rac1/p38 mitogen-Activated protein kinase pathway is required for interferon alpha-dependent transcriptional activation but not serine phosphorylation of Stat proteins. J Biol Chem 275: 27634-40
42. van Boxel-Dezaire AH, Rani MR, Stark GR. (2006). Complex modulation of cell type-specific signaling in response to type I interferons. Immunity 25: 361-72
43. Wenzel J, Uerlich M, Worrenkamper E, et al. (2005). Scarring skin lesions of discoid lupus erythematosus are characterized by high numbers of skin-homing cytotoxic lymphocytes associated with strong expression of the type I interferon-induced protein MxA. Br J Dermatol 153: 1011-5
44. Witte K, Gruetz G, Volk HD, et al. (2009). Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun 10: 702-14
45. Witte K, Witte E, Sabat R, et al. (2010). IL-28A, IL-28B, and IL-29: promising cytokines with type I interferon-like properties. Cytokine Growth Factor Rev 21: 237-51
46. Wolk K, Witte K, Witte E, et al. (2013). IL-29 is produced by T(H)17 cells and mediates the cutaneous antiviral competence in psoriasis. Sci Transl Med 5: 204ra129
47. Xu J, Lamouille S, Derynck R. (2009). TGF-beta-induced epithelial to mesenchymal transition. Cell Res 19: 156-72
48. Yin Z, Dai J, Deng J, et al. (2012). Type III IFNs are produced by and stimulate human plasmacytoid dendritic cells. J Immunol 189: 2735-45
49. Zahn S, Rehkamper C, Ferring-Schmitt S, et al. (2011). Interferon-Alpha stimulates TRAIL expression in human keratinocytes and peripheral blood mononuclear cells: implications for the pathogenesis of cutaneous lupus erythematosus. Br J Dermatol 165: 1118-23
50. Zahn S, Rehkamper C, Kummerer BM, et al. (2010). Evidence for a pathophysiological role of keratinocyte-derived type III interferon (IFNlambda) in cutaneous lupus erythematosus. J Investig Dermatol Symp Proc 131: 133-40
51. Zitzmann K, Brand S, Baehs S, et al. (2006). Novel interferon-lambdas induce antiproliferative effects in neuroendocrine tumor cells. Biochem Biophys Res Commun 344: 1334-41